

From the Chief Medical Officer
Dr Michael McBride



Department of
**Health, Social Services
and Public Safety**

www.dhsspsni.gov.uk

AN ROINN

**Sláinte, Seirbhísí Sóisialta
agus Sábháilteachta Poiblí**

MÁNNYSTRIE O

**Poustie, Resydënter Heisin
an Fowk Siccar**

Castle Buildings
Stormont Estate
Belfast BT4 3SQ
Tel: 028 9076 5615
Fax: 028 90523206
E-mail: [sgu-
niceguidance@dhsspsni.gov.uk](mailto:sgu-niceguidance@dhsspsni.gov.uk)

Circular HSC (SQSD) (NICE) 05/09 CG 58

Chief Executives of HSS Boards – **for distribution to:**

Directors of Public Health
Directors of Nursing
Directors of Pharmaceutical Services
Directors of Primary Care – for cascade to prescribing and GP
Advisors

Chief Executives of HSC Trusts – **for distribution to:**

Medical Directors – for cascade to relevant staff
Directors of Nursing – for cascade to relevant staff
Directors of Pharmaceutical Services – for cascade to relevant
staff

Date: 21 January 2009

General Practitioners

HSC Clinical and Social Governance Leads

Chief Executives of HSC Special Agencies and NDPBs

For Information

Chairs of HSS Boards
Chairs of HSC Trusts
Chief Executive, Regulation & Quality Improvement Authority
Chief Officers HSC Councils
Chief Executive/Postgraduate Dean, NIMDTA
Chief Executive, NIPPET
Chief Executive, NIPEC
Chief Executive, RMSC

Dear Colleagues

NICE Clinical Guideline No 58 – Prostate Cancer : diagnosis and treatment

This guideline covers the tests, treatment, care and support that men who have suspected or diagnosed prostate cancer should be offered. It does not specifically look at the care of men with rare cancers of the prostate (for example, small-cell carcinoma and rhabdomyosarcoma).

DHSSPS advises that this guidance is valid for Northern Ireland and endorses it for implementation in HSC.

The full NICE clinical guideline is available for download at:

<http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11924>

The HSC sector also should note that;

1. The Department expects HSC organisations to take account of this guidance in the planning and delivery of services to patients with prostate cancer.
2. This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
3. This guideline will be reviewed by NICE as and when required.
4. NICE has developed tools to help organisations implement this guidance. These are available at <http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11924> and include costing tools, implementation advice and audit criteria to monitor local practice.
5. NICE has developed related guidance on Prostate Cancer as follows:
 - Urological cancer and supportive and palliative care for adults with cancer, a clinical guideline on referral for suspected cancer CG27, available for download at <http://www.nice.org.uk/Guidance/CG27>
 - Guidance on docetaxel for the treatment of hormone-refractory prostate cancer TA101, available for download at <http://www.nice.org.uk/Guidance/TA101>
 - Interventional procedures guidance on cryotherapy, IPG119 & IPG145, available for download at <http://www.nice.org.uk/Guidance/IPG119>
<http://www.nice.org.uk/Guidance/IPG145>
 - Low- and high-dose brachytherapy, IPG132 & IPG174, available for download at <http://www.nice.org.uk/Guidance/IPG132>
<http://www.nice.org.uk/Guidance/IPG174>
 - High-intensity focused ultrasound for prostate cancer, IPG118 <http://www.nice.org.uk/Guidance/IPG118> and
 - Metastatic spinal cord compression, CG75 <http://www.nice.org.uk/Guidance/CG75>
6. NICE is developing guidelines on osteoporosis, date of publication to be confirmed and lower urinary tract symptoms in men, due for publication in February 2010.

All NICE guidance endorsed by the Department to date can be accessed on the DHSSPS website at <http://www.dhsspsni.gov.uk/sqsd-guidance-nice-guidance>

Circular HSS (PPMD) (NICE) 01/006 issued on 30 June 2006 provides further information on the Northern Ireland process for reviewing NICE guidance and further details on the local status of the Institute's guidance. This circular can be accessed at: http://www.dhsspsni.gov.uk/nice_guidance_01-06.pdf

A handwritten signature in black ink, appearing to read 'Michael McBride', written in a cursive style.

DR MICHAEL MCBRIDE
Chief Medical Officer